P1054: MYLOX-1: AN OPEN-LABEL, PHASE IIA STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR, GB2064, IN MYELOFIBROSIS

• C. Harrison,
• J. Mascarenhas,
• R. Rampal,
• D. Cilloni,
• B. Lindmark,
• B. Singh,
• B. Jacoby,
• S. Verstovsek

Affiliations

C. Harrison

1 Guy’s and St Thomas Hospital, London, United Kingdom

J. Mascarenhas

2 Icahn School of Medicine at Mount Sinai

R. Rampal

3 Memorial Sloan Kettering, New York, United States of America

D. Cilloni

4 University Hospital San Luigi Gonzaga, Orbassano, Italy

B. Lindmark

5 Galecto Inc, Copenhagen, Denmark

B. Singh

5 Galecto Inc, Copenhagen, Denmark

B. Jacoby

5 Galecto Inc, Copenhagen, Denmark

S. Verstovsek

6 MD Anderson Cancer Center, Houston, United States of America